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Abstract 
Glioma are glia-derived brain tumors that have poor prognosis. This thesis project tests Tyrosine Kinase 
Inhibitor drugs that have shown promise during an ongoing chemical drug screen on an alternate oncogenic 
pathway. In the ongoing chemical screen, tumors were induced in Drosophila melanogaster by expressing 
PtenRNAi to eliminate the tumor suppressor gene, Pten, which negatively regulates the Pi3K pathway. For 
this thesis project, tumors will be induced through constitutively activating the EGFR (epidermal growth 
factor receptor) through the Pi3K pathway. Therefore, these two projects individually look at two different 
types of glioma and aim to determine if certain drugs show promise on more than one type of glioma. A 
series of crosses over the course of three generations is performed to balance chromosomes of the flies and 
result in the genotype with the EGFR mutation. Data collection includes exposing these flies to the specific 
tyrosine kinase inhibitor drugs when added to their food. Larvae is collected, dissected to obtain the brains, 
washed and mounted on microscope slides after 2 and 3 days of exposure to the drugs. Images are taken of 
the mounted brains for further data analysis. In order to conclude if these drugs showed similar promise as 
in the existing chemical screen, images will be examined for enhancement, suppression or no effect in 
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 Today, cancer is still one of the leading causes of death and results in 8.2 million 
people deaths a year (National Cancer Institute, 2018). Of these deaths, about 13,000 of 
these cancer deaths are from brain cancer, and specifically 9,100 suffered from 
aggressive form of glioma. Glioma are glia-derived brain tumors with poor prognosis. 
Current treatments for glioma include surgery, chemotherapy and radiotherapy (John’s 
Hopkins Medicine). While these treatments target tumorous cells, these treatments also 
effect healthy cells. Therefore, these patients’ lives are usually only extended by a few 
months (Brennan et al., 2013). The lack of life-extending treatments calls for research in 
treatments that can provide better prognosis.   
There are a variety of mutations that can lead to the development of glioblastoma. 
Some mutations are specific to glioblastoma, while others are common cancer mutations. 
TP53 and PTEN are common cancer mutations (Liu, 2016). PTEN is a tumor suppressor 
gene and these mutations usually result in the loss of function. In addition, point 
mutations in EGFR is also common. EGFR mutations result in EGFR amplification. 
Other common mutations found in glioblastoma include Pi3KCA and Pi3KR1, NF1, RB1, 
and IDH1 (Liu 2016). Many of these genes regulate cell signaling involving cell 
proliferation and survival (Liu 2016). 
The development of glioma is important in understanding the prognosis of this 
type of cancer and the need for better treatment. As previously mentioned, glioma are 
glia-derived brain tumors. Glia cells are products down the line of neuroblast cell division 
(Figure 1). Neuroblasts undergo asymmetric cell division (Homem et al., 2012). In 
Drosophila, division results in two daughter cells, either a ganglion mother cell or 
another neuroblast that will undergo further division into two more daughter cells. 
Ganglion mother cells then divide into a neuron and glia cell. In humans, neuroblast 
division is more complex, involving the transit amplification of interneurons. Using 
Drosophila as a model organism is beneficial due to their simpler central nervous system 
and neuroblast division. This division can be important in understanding the development  
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of glioma depending on the rounds of cell division in development. The amount of 
neuroblasts can be determined in Miranda staining, whereas the amount of Ganglion  
Mother cells can be determined through Prospero staining (Brody, 1996). These two 
stains have been beneficial in analyzing the production of tumors in model organisms.  
 Drosophila melanogaster is the model organism used in this experiment and has 
been a pivotal model organism in scientific research. This model organism is beneficial in 
scientific research due to its accessibility, ease in maintaining, and their short life spans 
(Figure 2). Drosophila has led to many scientific discoveries and has been used in 
studying many diseases such as cancer, cardiovascular disease, neurological diseases and 
diseases related to the immune system (Fortini et al., 2000). Another important aspect of 
Drosophila are the similarities their genomes share with humans. 70% of human disease-
linked genes are seen in Drosophila (Chien et al, 2002; Hirth, 2010; Pandley and Nichols, 
2011; Read, 2011), as well as important cellular signaling pathways such as Wnt, Hippo, 
Notch, Pi3K and EGFR (Read, 2011; Tickoo and Russell, 2002).  
 The signaling pathways mentioned are important in cellular mechanisms such as 
growth, development and cell proliferation (Figure 3). When these signaling pathways 
are mutated or do not operate as they should, cancer can result. Glioblastomas are 
associated with many different mutations in these oncogenic pathways (Phillips et al, 
2006; Verhaak et al., 2002). Many glioblastomas include mutation that leads to 
overexpression of receptors of tyrosine kinases like EGFR (Read, 2013). Tyrosine 
kinases are important in signaling cascades in cells that activate specific genes (Paul et 
al., 2004).  In normal functioning cells, tyrosine kinases like EGFR are important for 
cellular functions. For example, cell proliferation is promoted (Huang et al., 2007). 
However, in mutant EGFR, the kinase is constitutively active and therefore, constantly 
stimulates RAS that promotes migration and blocks apoptosis leading to tumor 
development (Boockvar et al., 2003). However, glioma requires activation of two of these 
genetic pathways to result in cancer. In humans, the most common oncogenic pathways 
activated are the co-activation of EGFR and Pi3K (Raizer, 2011). Modeling this co-
activation in Drosophila to induce glioblastoma is the critical first step in this thesis 
project. The effectiveness of specific tyrosine kinase inhibitor drugs that had showed  
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interesting results on glioma induced by a Pten mutation through the RAS pathway are 
tested on a different mutation for this thesis project. The previous drug screen focused on 
glioma induced through a negative mutation, while this project focuses on an EGFR 
mutation that is constitutively active. 
















Neuroblast stem cells undergo asymmetric cell division. They can divide to 
self-renew into another neuroblast or into ganglion mother cells (GMC) that 
further divide into a glia cell or neuron. Each cell type can be identified based 
on biomarkers like Miranda for Neuroblasts and Prospero for GMC.  
 













Figure 2 (Maynard, 2009) 
 
In this figure, the life cycle of Drosophila is shown, 
along with the timeframe of each stage. The short 
lifespan from embryo, larvae and adult provides 
advantages in the research field to complete many 
trials or experiments in a short amount of time.  
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Figure 3 (Rybak, 2014) 
 
These signaling pathways including Ras, Pi3K, and STAT3 converge and act directly 
or cross actively to mediate tumorigenesis. If mutations in these pathways or present 
receptors are found, tumors such as GBM can result.  
 





Drosophila crosses to generate Pi3K EGFRλtop glioma: 
The overall drug screen consists of seven steps and the drugs tested throughout 
this project were P1A9 and P1G10. As mentioned, modeling the co-activation of the 
EGFR and Pi3k pathway is the critical first step in inducing glioblastoma in the model 
organism. The co-activation of these pathways required a series of steps over the course 
of three generations of Drosophila. This is accomplished with balancer chromosomes. 
Balancer chromosomes are specific stocks in Drosophila that are rearranged 
chromosomes that can be used to maintain a mutant genotype or help in complex 
genotype construction (Miller et al., 2018). However, lethality is a possible issue with 
these oncogenic mutations and can cause issues determining crossing schemes to obtain 
specific genotypes. For this project, three generations of crosses were completed to obtain 
the final genotype for the Pi3k; Repo stock (Figure 4). In each generation, female virgins 
are collected and used in the next step. Recombination, or genetic exchange between 
chromosomes, occurs in female flies (John et al., 2016). Using female virgins eliminates 
the risk of recombination when trying to obtain a specific genotype. Once this genotype 
was obtained, the stock was crossed with EGFRλtop resulting in the final cross with 
induced glioma. Once glioma was successfully induced in Drosophila, the final cross and 
final balanced stocks were maintained with a 2:1 female to male ratio to result in 
maximal egg production for data collection.  
 
Drug Screen:  
Larvae from control stocks and the Pi3K; Repo X EGFRλtop cross are collected on 
day 3 of their life span when they are in their early third instar stage (Figure 2). Third 
instar larvae are added to food that has been infused with the specific tyrosine kinase 
inhibitor chemicals. The larvae are exposed to the inhibitor drugs for an additional 3 days 
and are collected again at day 5 and 6 of age. When collected after exposure, the larvae 
are dissected to obtain the brain and ventral cord. Before imaging, the dissection is  
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successfully prepared. Following dissection, larvae samples are fixed for 20 minutes in 
150 microliters of PBS and 50 microliters of 16% PFA. The larvae samples are then 
washed for 10 minutes in 1mL of PBS-T. The sample is then mounted onto microscope 
slides for imaging and are protected and secured by Vectashield (Vector Labs, USA). 




 In addition to images following drug exposure, Miranda staining is also 
completed in attempts to explain tumor progression. Larvae was dissected and prepared 
similarly to the samples prepared after drug exposure. Following fixing, Miranda 
antibody 1:200 dilution is added to the sample and incubated overnight at 4°C.  The 
primary antibody is removed, and the samples washed with PBST, then incubated with 
the appropriate secondary antibody fused to a fluorophore (e.g. anti-mouse Cy3). After 
2h the samples are washed for a series of 3 rounds of 10 minute washes. The stained 
brains are mounted and protected with Vectashield (Vector Labs, USA). The stained 
slides are imaged using confocal microscopy (Olympus Fluoview 3000).  
 
Quantification of data: 
 Quantification of data was completed by analyzing the central brain region, or the 
CBR. The CBR is located between the two occipital disks and ventral cord (Figure 5). 
The width of the CBR was measured in pixels. These widths were then compared 
between the crosses and controls exposed to drug treatment to determine the effects. 
Suppression was seen if the size of the CBR decreased in comparison to the cross 
untreated and is more similar to the size of the control. Likewise, enhancement was 














A series of crosses were designed with balancer chromosomes to obtain 
the wanted genotype for Pi3k; Repo to induce tumor when crossed with 
EGFRλtop. This was accomplished over three generations.  











The CBR is located in between the two occipital 
lobes of the brain. The ventral nerve cord is the 
posterior part of the Drosophila brain.  





The Pi3K EGFRλtop model of glioma growth:  
 The Pi3k EGFRλtop model of glioma growth showed similar results when 
compared to the Pteni; RasV12 model. In both models, there was a significant increase in 
size of the CBR when the cross was compared to the control. In Figure 6, this significant 
difference is observed. In both studies, the controls showed a CBR of 145-170 pixels in 
width. In both mutations, the crosses showed an enhanced CBR of 230 pixels in width.   
Following the completion of the cross scheme for co-activation of Pi3K and 
EGFR and prior to drug exposure, control images were completed and analyzed for both 
the control stock and the cross (Figure 7C). The area examined for analysis was the 
central brain region (CBR). This region was analyzed by determining the average width 
of the central brain region in pixels for both the control stock and co-activated cross 
(Figure 7B). On average, the control stock showed CBR of 455.50 pixels, whereas the co-
activated cross showed a larger CBR of 707.25 pixels (Figure 7A).  
Miranda staining was completed and analyzed to compare Repo control to the 
Pi3k; Repo X EGFR cross to explain glia overgrowth. Miranda staining can be seen in the 
red stained cells showing successful staining of neuroblast stem cells (Figure 8). 
Distribution of neuroblast cells, size and number were analyzed n the comparison. 
Miranda staining, when compared to control and cross, revealed the cells in the cross are 
not clearly or evenly distributed and vary in size. In the control, they are widely spaced 
and similar in size across the CBR. 
 
Drug screening in Pi3K EGFR model: 
As mentioned, P1A9 and P1G10 had previously shown interesting effects on 
tumor progression when examined with the Pten mutation via the RAS pathway. The 
drug screen steps were the same between both mutations examined. These specific 
tyrosine kinase inhibitors were tested on the Pi3K; Repo X EGFR mutation to determine 
if the effects were similar for a different mutation. The size of the CBR in the Pteni;  
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RasV12 mutation after drug exposure for three days showed enhancement from P1A9 and 
suppression for P1G10 when compared to the Repo control (Figure 9).   
 P1A9 and P1G10 showed interesting effects on with the Pi3K; Repo X EGFR 
mutation as well. The control when exposed to P1A9 for three days had CBR on average 
of 460 pixels in width After 3 days of drug exposure, the cross on average exhibited a 
CBR width of 928 pixels (Figure 10). In comparison, after three days of exposure to 
P1G10, no larvae surfaced for the control drug vials. In addition, very few (3/20) larvae 
rose across the 3 drug vials. Of the larvae surfaced and dissected, extremely fragile brain 









This figure shows the comparison between the studies of the two different mutations. 
In both studies, the controls show a CBR of 140-170 pixels. In addition, in both 
studies the activated mutations show a CBR 230 pixels.  





On average, the CBR was larger in the co-activated cross (A). This was analyzed from 4 brains in both 
genotypes (B). The images were completed using fluorescent microscopy (C).  









Miranda staining is visible in the red stained neuroblast cells. The cross (right) 
shows inconsistency in size, number and distribution of neurbolast cells when 
compared to the Repo control.  


























P1A9 showed enhancement of CBR through the Pteni; RasV12 mutation, whereas 
P1G10 showed suppression of the tumor.  







P1A9 showed an increase in the width of the CBR in the cross when compared to the control.  






P1G10 had reduction in CBR in comparison to the 
untreated control. The treated control had death of larvae 



















 The increase in the width of the CBR in Pi3K; Repo X EGFR cross in comparison 
to the control stock seen in Figure 6 in conjunction with results from Miranda staining 
supported successful co-activation of the Pi3K pathway and EGFR pathway for 
tumorigenesis. Further, the unequal distribution, increase in size and number of 
neuroblast cells in the cross compared to the Repo control explains how tumor 
progression may occur. An increase in number of neuroblast stem cells and unequal 
distribution can result in greater number and unequal distribution of glia seen in glioma 
tumors due to the asymmetric cell division these stem cells undergo. Determining 
successful co-activation of these oncogenic pathways and successful tumor progression 
was important before the tyrosine kinase inhibitor drugs were tested.  
 P1A9 and P1G10 showed interesting effects on tumor progression for the Pteni; 
RasV12 mutation. P1A9 showed enhancement across the CBR, while P1G10 showed 
suppression across the CBR. When these two drugs were examined with the Pi3K; Repo 
X EGFR mutation, P1A9 showed similar results. Enhancement was seen across the CBR 
after three days of exposure when compared to the control. However, P1G10 showed an 
interesting response after drug exposure for this constitutively active mutation. P1G10 
indicated possible suppression, as well as possible lethality. Larvae images were unable 
to be obtained for the control, as larvae did not survive to day three following the 
addition to the drug vials. In addition, the larvae dissected for the cross that arose in small 
numbers had extremely fragile brains. The reduction in size of the CBR compared to the 
untreated control images indicated possible suppression; however, the fragility and lack 











 In conclusion, this thesis project tested specific tyrosine kinase inhibitor drugs 
that had shown interesting effects on a negative mutation, Pten, through the RAS 
pathway on a constitutively active mutation of EGFR through the Pi3K pathway. The 
critical first step of co-activating the EGFR and Pi3K pathway was successfully 
accomplished through a series of crosses across three generations. The successful 
genotype completion was seen through control images and Miranda staining. The two 
specific tyrosine kinase inhibitor drugs tested were P1A9 and P1G10. P1A9 had shown 
enhancement when tested on Pteni; RasV12 mutation. Enhancement was also observed 
when P1A9 was tested on Pi3K; Repo X EGFR mutation. P1G10 had shown promising 
suppression when tested on the Pteni; RasV12 mutation. P1G10 indicated possible 
suppression when compared to the untreated control. Most importantly, P1G10 also 
indicated possible lethality on this specific mutation. Future directions include retesting 
P1G10 to examine this possible lethality and determine if suppression or lethality is 
observed. In addition, other tyrosine kinase inhibitor drugs that had shown promising 
effects on the original drug screen should be tested to further examine the Pi3K; Repo X 
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